A recent study by a team at Johns Hopkins University has sparked new concerns about rosuvastatin, a widely used drug for lowering cholesterol.
This medication, which belongs to a group called statins, is taken by many people to control high cholesterol levels. Statins are known for their ability to keep cholesterol under check effectively, with rosuvastatin being one of the preferred options.
The research points to a worrying possibility: higher doses of rosuvastatin might not be as safe for the kidneys as previously thought. This is a significant development, as it challenges the existing understanding of how this drug should be prescribed and used.
When rosuvastatin was first approved by the U.S. Food and Drug Administration (FDA), there were already hints that it could have negative effects on the kidneys, such as causing blood or protein to appear in the urine. However, the extent of these risks in everyday use has not been clear until now.
The researchers at Johns Hopkins took a deep dive into the health records of people from 2011 to 2019.
They compared the outcomes of those taking rosuvastatin with others using atorvastatin, another statin. Their study included records from over 150,000 rosuvastatin users and nearly 800,000 atorvastatin users.
Over a three-year period, they observed that about 2.9% of the patients showed signs of blood in their urine, and 1.0% had protein in their urine. More troubling, however, was the discovery that rosuvastatin seemed to increase the risk of these issues more than atorvastatin.
Specifically, there was an 8% higher risk of blood in the urine, a 17% higher risk of protein in the urine, and a 15% higher risk of severe kidney failure (which might need treatments like dialysis or a kidney transplant) with rosuvastatin use.
The situation seemed even more concerning for patients with advanced kidney disease. Astonishingly, 44% of these patients were given higher doses of rosuvastatin than what the FDA recommends for those with kidney issues.
Despite these findings, both rosuvastatin and atorvastatin were similarly effective in benefiting the heart, which brings up a crucial question: Is the slight risk increase worth it, especially for those already dealing with kidney problems?
Published in the Journal of the American Society of Nephrology, the study led by Jung-im Shin and the team suggests a need for a careful reconsideration of how rosuvastatin is prescribed, especially in higher doses.
It calls for doctors and patients to think more carefully about the balance between the benefits and potential risks, especially concerning kidney health.
This study highlights the critical role of continuous research and monitoring of medications after they become widely available.
As we learn more about how drugs work in real-world settings, medical advice and prescriptions can be updated to better safeguard patient health and safety.
If you care about nutrition, please read studies about how Mediterranean diet could protect your brain health, and the best time to take vitamins to prevent heart disease.
For more information about health, please see recent studies about plant nutrients that could help reduce high blood pressure, and these antioxidants could help reduce dementia risk.
Copyright © 2024 Knowridge Science Report. All rights reserved.
